TWI704155B - 雙特異性抗體之純化平台 - Google Patents

雙特異性抗體之純化平台 Download PDF

Info

Publication number
TWI704155B
TWI704155B TW104123813A TW104123813A TWI704155B TW I704155 B TWI704155 B TW I704155B TW 104123813 A TW104123813 A TW 104123813A TW 104123813 A TW104123813 A TW 104123813A TW I704155 B TWI704155 B TW I704155B
Authority
TW
Taiwan
Prior art keywords
protein
buffer
affinity matrix
affinity
polypeptide
Prior art date
Application number
TW104123813A
Other languages
English (en)
Chinese (zh)
Other versions
TW201617359A (zh
Inventor
安卓 圖斯汀
克里斯汀 安迪寇特
班傑明 亞當斯
約翰 馬提拉
漢納 巴克
Original Assignee
美商再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商再生元醫藥公司 filed Critical 美商再生元醫藥公司
Publication of TW201617359A publication Critical patent/TW201617359A/zh
Application granted granted Critical
Publication of TWI704155B publication Critical patent/TWI704155B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3819—Affinity chromatography of the nucleic acid-nucleic acid binding protein type
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26—Cation exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW104123813A 2014-07-26 2015-07-23 雙特異性抗體之純化平台 TWI704155B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029463P 2014-07-26 2014-07-26
US62/029,463 2014-07-26

Publications (2)

Publication Number Publication Date
TW201617359A TW201617359A (zh) 2016-05-16
TWI704155B true TWI704155B (zh) 2020-09-11

Family

ID=53836215

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104123813A TWI704155B (zh) 2014-07-26 2015-07-23 雙特異性抗體之純化平台

Country Status (19)

Country Link
US (1) US10626142B2 (https=)
EP (2) EP3912987B9 (https=)
JP (1) JP6702967B2 (https=)
KR (1) KR102440737B1 (https=)
CN (1) CN107074906B (https=)
AR (1) AR101262A1 (https=)
AU (1) AU2015298156B2 (https=)
DK (2) DK3912987T3 (https=)
EA (1) EA036154B1 (https=)
ES (2) ES2942533T3 (https=)
FI (1) FI3912987T3 (https=)
IL (1) IL255198B (https=)
MX (1) MX377558B (https=)
MY (1) MY187051A (https=)
PL (2) PL3912987T3 (https=)
SG (2) SG11201700157VA (https=)
TW (1) TWI704155B (https=)
WO (1) WO2016018740A2 (https=)
ZA (1) ZA201700622B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US10294306B2 (en) * 2015-05-28 2019-05-21 Bio-Rad Laboratories, Inc. Affinity ligands and methods relating thereto
AU2016381992B2 (en) * 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
EP4549463A3 (en) * 2016-06-17 2025-07-30 F. Hoffmann-La Roche AG Purification of multispecific antibodies
WO2018038469A1 (ko) * 2016-08-20 2018-03-01 (주)아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
KR101933656B1 (ko) 2016-08-20 2018-12-28 (주) 아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
GB201805142D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Bioprocess R&D Ab Separation method
MY207066A (en) * 2018-08-17 2025-01-28 Regeneron Pharma Method and chromatography system for determining amount and purity of a multimeric protein
SG11202102713TA (en) * 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
WO2020066270A1 (ja) * 2018-09-28 2020-04-02 株式会社カネカ κ鎖可変領域を含む抗体および／または抗体断片の製造方法
JP2022514122A (ja) 2018-10-31 2022-02-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質を同定及び定量化する方法及びシステム
CA3110377A1 (en) 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. Anti-staphylococcus antibodies and uses thereof
CN112996801A (zh) * 2018-11-26 2021-06-18 北卡罗来纳州大学 用于捕获宿主细胞蛋白的肽配体
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
IL319262A (en) 2018-12-24 2025-04-01 Sanofi Sa Multispecific FAB pseudoproteins bind
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
EP3983015A1 (en) 2019-06-11 2022-04-20 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
WO2020252260A1 (en) * 2019-06-13 2020-12-17 Regeneron Pharmaceuticals, Inc. Methods for removing undesired components during multistage chromatographic processes
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
CA3163017A1 (en) * 2019-12-26 2021-07-01 Daehae SONG Method for purifying biologically active peptide by using protein a affinity chromatography
KR102834449B1 (ko) 2019-12-27 2025-07-15 케이에스광학주식회사 투명한 방탄 적층 구조물
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
JP2024504388A (ja) * 2021-01-25 2024-01-31 ユーハン・コーポレイション 抗４－１ｂｂ／抗ｈｅｒ２二重特異性抗体の精製方法
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法
WO2023247468A2 (en) * 2022-06-22 2023-12-28 Puridify Limited Kappa light chain-binding convection matrix
WO2024123698A1 (en) 2022-12-08 2024-06-13 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
CN116769044A (zh) * 2023-07-11 2023-09-19 康日百奥生物科技(苏州)有限公司 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法
WO2025073922A1 (en) * 2023-10-04 2025-04-10 Sartorius Bia Separations D.O.O. Enhanced chromatographic separations of components in a mixture by employing chaotropic elution
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化
WO2025131519A1 (en) * 2023-12-21 2025-06-26 Cytiva Bioprocess R&D Ab Antibody separation with a vh3 binding separation matrix
WO2025173342A1 (ja) * 2024-02-13 2025-08-21 Jsr株式会社 Ｆｃ融合タンパク質を精製するためのクロマトグラフィー用担体、及びそれを用いたＦｃ融合タンパク質の精製方法
WO2026075981A1 (en) * 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Methods of analyzing heterodimeric proteins

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DK0826695T3 (da) 1996-09-03 2002-04-15 Gsf Forschungszentrum Umwelt Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
WO2000018435A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
US7169903B2 (en) 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20030224000A1 (en) 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
ZA200710330B (en) 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
SG149759A1 (en) * 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
US20110166332A1 (en) * 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MY192182A (en) * 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
CA2785414C (en) * 2009-12-25 2019-01-22 Tomoyuki Igawa Polypeptide modification method for purifying polypeptide multimers
PT3434767T (pt) * 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
EP2500073A1 (en) * 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
EP3517548A1 (en) * 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
AU2013322710A1 (en) * 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos

Also Published As

Publication number Publication date
EP3172221B1 (en) 2021-07-07
EA036154B1 (ru) 2020-10-06
JP6702967B2 (ja) 2020-06-03
WO2016018740A3 (en) 2016-03-17
BR112017001443A2 (pt) 2017-12-05
SG10201900661YA (en) 2019-02-27
AR101262A1 (es) 2016-12-07
EP3172221A2 (en) 2017-05-31
WO2016018740A2 (en) 2016-02-04
MX2017001217A (es) 2017-05-03
CN107074906A (zh) 2017-08-18
MY187051A (en) 2021-08-27
SG11201700157VA (en) 2017-02-27
PL3912987T3 (pl) 2023-07-24
EA201790247A1 (ru) 2017-08-31
FI3912987T3 (fi) 2023-06-19
US20160024147A1 (en) 2016-01-28
IL255198B (en) 2022-04-01
EP3912987B9 (en) 2023-05-31
IL255198A0 (en) 2017-12-31
MX377558B (es) 2025-03-10
DK3912987T3 (da) 2023-05-01
DK3172221T3 (da) 2021-08-09
KR102440737B1 (ko) 2022-09-06
ES2881026T3 (es) 2021-11-26
EP3912987A1 (en) 2021-11-24
ZA201700622B (en) 2020-05-27
WO2016018740A8 (en) 2021-06-10
CN107074906B (zh) 2021-05-14
US10626142B2 (en) 2020-04-21
KR20170035941A (ko) 2017-03-31
ES2942533T3 (es) 2023-06-02
EP3912987B1 (en) 2023-03-22
AU2015298156A1 (en) 2017-02-23
JP2017524740A (ja) 2017-08-31
PL3172221T3 (pl) 2021-12-27
CA2955618A1 (en) 2016-02-04
TW201617359A (zh) 2016-05-16
NZ728700A (en) 2023-09-29
AU2015298156B2 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
TWI704155B (zh) 雙特異性抗體之純化平台
JP2025102816A (ja) 多段階クロマトグラフィープロセス中の望ましくない成分を除去する方法
HK40062836B (en) Purification platform for bispecific antibodies
HK40062836A (en) Purification platform for bispecific antibodies
CA2955618C (en) Purification platform for bispecific antibodies
US20230242579A1 (en) Methods for Improving Resolution of Heterodimeric Proteins from Impurities Using Affinity Chromatography
EA045004B1 (ru) Способы удаления нежелательных компонентов в многостадийных хроматографических процессах
EA049572B1 (ru) Способы удаления нежелательных компонентов в многостадийных хроматографических процессах
BR112017001443B1 (pt) Método para fabricação de uma proteína
HK1234069B (en) Purification platform for bispecific antibodies
NZ728700B2 (en) Purification platform for bispecific antibodies
EA049692B1 (ru) Способы для улучшения отделения гетеродимерных белков от примесей с применением аффинной хроматографии